Abstract:Computational toxicology models have been successfully implemented to prioritize and screen chemicals. There are numerous in silico (quantitative) structure–activity relationship ([Q]SAR) models for the prediction of a range of human-relevant toxicological endpoints, but for a given endpoint and chemical, not all predictions are identical due to differences in their training sets, algorithms, and methodology. This poses an issue for high-throughput screening of a large chemical inventory as it necessitates several models to cover diverse chemistries but will then generate data conflicts. To address this challenge, we developed a consensus modeling strategy to combine predictions obtained from different existing in silico (Q)SAR models into a single predictive value while also expanding chemical space coverage. This study developed consensus models for nine toxicological endpoints relating to estrogen receptor (ER) and androgen receptor (AR) interactions (i.e., binding, agonism, and antagonism) and genotoxicity (i.e., bacterial mutation, in vitro chromosomal aberration, and in vivo micronucleus). Consensus models were created by combining different (Q)SAR models using various weighting schemes. As a multi-objective optimization problem, there is no single best consensus model, and therefore, Pareto fronts were determined for each endpoint to identify the consensus models that optimize the multiple-criterion decisions simultaneously. Accordingly, this work presents sets of solutions for each endpoint that contain the optimal combination, regardless of the trade-off, with the results demonstrating that the consensus models improved both the predictive power and chemical space coverage. These solutions were further analyzed to find trends between the best consensus models and their components. Here, we demonstrate the development of a flexible and adaptable approach for in silico consensus modeling and its application across nine toxicological endpoints related to ER activity, AR activity, and genotoxicity. These consensus models are developed to be integrated into a larger multi-tier NAM-based framework to prioritize chemicals for further investigation and support the transition to a non-animal approach to risk assessment in Canada.

Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

The database makes the poison: How the selection of datasets in QSAR models impacts toxicant prediction of higher tier endpoints

Quantitative structure–toxicity relationships in translational toxicology

Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases

QSAR Tools for Toxicity Prediction in Risk Assessment—comparative Analysis

Generating Model Integrated Evidence for Generic Drug Development and Assessment

Awareness and use of quantitative decision-making methods in pharmaceutical development

Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update report

Understanding and overcoming the technical challenges in using in silico predictions in regulatory decisions of complex toxicological endpoints - A pesticide perspective for regulatory toxicologists with a focus on machine learning models

Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective

Ecotoxicological risk assessment of active pharmaceutical ingredients (APIs) against different aquatic species leveraging intelligent consensus prediction and i-QSTTR modeling

Better prediction of the local concentration-effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development

Ecotoxicological risk assessment of pesticides against different aquatic and terrestrial species: using mechanistic QSTR and iQSTTR modelling approaches to fill toxicity data gap

Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

The convergence of pharmacometrics and quantitative systems pharmacology in pharmaceutical research and development

QSAR Modeling: Where Have You Been? Where Are You Going To?

Applying quantitative structure–activity relationship approaches to nanotoxicology: Current status and future potential

QSAR models for predicting in vivo reproductive toxicity

Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists

Development and application of consensus in silico models for advancing high-throughput toxicological predictions